Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.51 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | VEGFA | P15692 | 4/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30546891 | 1.00 | EGLN1 (0.51) | EGLN1EGLN3FLT1VEGFAFTO | |
| Formic Acid SCHEMBL30454639 | 0.96 | EGLN1 (0.47) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL30546813 | 0.88 | EGLN1 (0.44) | EGLN1EGLN3FLT1VEGFA | |
| SCHEMBL24257726 | 0.88 | EGLN1 (0.44) | EGLN1EGLN3FLT1VEGFA | |
| SCHEMBL30546834 | 0.85 | EGLN1 (0.56) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL24257601 | 0.85 | EGLN1 (0.56) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL24257518 | 0.80 | EGLN1 (0.50) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL30546885 | 0.80 | EGLN1 (0.50) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL24257542 | 0.80 | EGLN1 (0.67) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL24257682 | 0.78 | EGLN3 (0.55) | EGLN1EGLN3FLT1VEGFAFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885EGLN3 2/4885FLT1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.